Inventiva provides a corporate update and reports its unaudited 2024 first-half financial results Recruitment in NATiV3 clinical trial progresses with over 85% of the targeted number of patients enrolled in the main cohort and a statistical powering of the study expected to be superior to 95% for both doses evaluated in the trial.Baseline characteristics of patients randomized in the main cohort of NATiV3 remain consistent with the characteristics of patients enrolled in the completed Phase IIb, NATIVE, clinical trial.Blinded analyses of patients in NATiV3 suggest a positive evolution of k...
Inventiva fait un point sur ses activités et publie ses résultats financiers non audités du premier semestre 2024 Le recrutement dans l'étude clinique NATiV3 progresse, avec plus de 85 % du nombre cible de patients randomisés dans la cohorte principale et d'une puissance statistique de l'étude qui devrait être supérieure à 95 % pour les deux doses évaluées dans l’étude .Les caractéristiques de base des patients randomisés dans la cohorte principale de NATiV3 sont cohérentes avec celles des patients randomisés dans l'étude clinique de Phase IIb, NATIVE, qui est terminée.Les analyses en aveu...
This conference booklet is your guide to our Life Sciences Conference set to take place on Thursday, 26 September 2024 at our historic building at Grand Place in Brussels. This event offers the possibility to have one-on-one meetings and/or join pitch sessions with the following companies and their top management: Public: AUTOLUS | GALAPAGOS | HYLORIS | INVENTIVA | MAAT PHARMA | ONWARD MEDICAL | SEQUANA MEDICAL | UCB | ZEALAND PHARMA Private: CONFO TX | MRM HEALTH | PANTERA | SKYLINE DX
Inventiva reported uneventful preliminary 1H24 results. The next important milestone for the company is the last patient first visit (LPFV) in the phase 3 (NATiV3) trial of lanifibranor, for which the timeline guidance remains at 2H24 – this event would provide timeline certainty, pinning the timeline for the topline readout to early 2H26. Inventiva's cash runway was extended through September 2024 (previously early 3Q24) by the previously reported royalty certificates of approx. € 20m, which in...
Inventiva Reports Preliminary 2024 First-Half Financial Information¹ Cash and cash equivalents at €10.1 million as of June 30, 2024, compared to cash and cash equivalents at €26.9 million, €0.012 million of short-term deposits and €9.03 million of long-term deposits as of December 31, 2023.On July 18, 2024, Inventiva issued royalty certificates subscribed by Samsara BioCapital and existing shareholders (BVF Partners, NEA, Sofinnova and Yiheng) for an amount of approximately €20.1 million.No Revenues recorded in H1 2024, compared to €1.9 million for the same period in 2023. Daix (France...
Inventiva secures a new patent in Japan, expanding the IP protection of its lead product candidate lanifibranor Japanese Patent Office approved Inventiva’s patent application relating to the use of lanifibranor for the treatment of cirrhosis.1This patent strengthens Inventiva’s intellectual property with respect to lanifibranor in Japan for the indication cirrhosis, including cirrhosis due to MASH/NASH. Daix (France), Long Island City (New York, United States), July 25, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutica...
Inventiva obtient un nouveau brevet au Japon, élargissant la protection de la propriété intellectuelle de lanifibranor ► L'Office des brevets japonais a accordé la demande de brevet d'Inventiva concernant l'utilisation de lanifibranor pour le traitement de la cirrhose1. ► Ce brevet renforce la propriété intellectuelle d’Inventiva concernant lanifibranor dans l’indication cirrhose, y compris la cirrhose due à la MASH/NASH. Daix (France), Long Island City (New York, États-Unis), le 25 juillet 2024 – Inventiva (Euronext Paris et Nasdaq: IVA) (« Inventiva » ou la « Société »), société biop...
Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux Daix (France), Long Island City (New York, United States), July 19, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with metabolic dysfunction-associated steatohepatitis (“MASH”), also known as non-alcoholic steatohepatitis (“NASH”), and other diseases with significant unmet medical needs, today announced the half-year report of its liquidity contract wit...
Bilan semestriel du contrat de liquidité de la société Inventiva conclu avec Kepler Cheuvreux Daix (France), Long Island City (New York, Etats-Unis), le 19 juillet 2024 – Inventiva (Euronext Paris et Nasdaq: IVA) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement clinique de petites molécules administrées par voie orale pour le traitement des patients atteints de stéatohépatite associée à un dysfonctionnement métabolique (« MASH »), également connue sous le nom de stéatohépatite non alcoolique (« NASH »), et d’autres maladies avec un besoin médic...
Inventiva announced the issuance of €20.1m in royalty certificates in return for a 3% royalty on lanifibranor sales in the US, EU and UK subscribed by Samsara BioCapital, and existing investors BVF Partners, NEA, Sofinnova, and Yiheng. This extends the company's runway through September 2024 (previously early 3Q24), providing Inventiva with breathing room over the summer to work towards completion of recruitment in the phase 3 (NATiV3) trial of lead asset lanifibranor in NASH/MASH (last patient ...
Inventiva annonce l'émission de certificats de royalties pour un montant de 20,1 millions d'euros Certificats de royalties souscrits par Samsara BioCapital et des actionnaires existants BVF Partners, NEA, Sofinnova et Yiheng.Royalties de 3 % sur les ventes nettes futures du lanifibranor aux Etats Unis, dans l’Union européenne et au Royaume Uni, sur une période de 14 ans.Position de trésorerie étendue jusqu'à fin septembre 2024 et poursuite de l’évaluation des options stratégiques et financières1. Daix (France), Long Island City (New York, États-Unis), le 18 juillet 2024 – Inventi...
Inventiva provides an update on its NATiV3 clinical program evaluating lanifibranor in patients with MASH/NASH and its financial position Recruitment in NATiV3 clinical trial continues in both cohorts with over 80% of the targeted number of patients enrolled in the main cohort and 100% in the exploratory cohort of NATiV3.Analysis of the baseline characteristics of all patients randomized in the main cohort of NATiV3 show a patient profile similar to patients randomized in the NATIVE Phase IIb clinical trial.A blinded analysis of all randomized patients suggests weight gain plateaus and s...
Description of the Share Repurchase Program Authorised by the Ordinary General Meeting of 20 June 2024 Daix, 21 June 2024 Pursuant to Article 241-2 of the AMF General Regulations (Règlement Général de l’Autorité des marchés financiers), the purpose of this description is to present the objectives and terms of the Company’s share repurchase program approved by the Ordinary General Meeting of 20 June 2024, it being specified that the Company does not to date intend to pursue any objective other than to animate the market under a liquidity agreement which has been in place since the...
Results of the votes of the Combined Shareholders’ General Meeting of June 20, 2024 Daix (France), Long Island City (New York, United States), on June 21, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), also known as non-alcoholic steatohepatitis (“NASH”), and other diseases with significant unmet medical needs, today announced the results of the votes of its Combined Shareholders’ Meeting...
Résultats des votes de l’Assemblée Générale Mixte des actionnaires réunies le 20 juin 2024 Daix (France), Long Island City (New York, Etats-Unis), le 21 juin 2024 – Inventiva (Euronext Paris et Nasdaq : IVA) (la « Société »), société biopharmaceutique spécialisée dans le développement clinique de petites molécules administrées par voie orale pour le traitement de la stéatohépatite associée à un dysfonctionnement métabolique (« MASH »), également connue sous le nom de stéatohépatite non alcoolique (« NASH ») et d’autres maladies avec un besoin médical non satisfait significatif, annonce les ...
Yesterday, competitor Lilly (no coverage) reported a statistically significant effect on fibrosis in the phase 2 (SYNERGY-NASH, NCT04166773) trial of tirzepatide (GIP/GLP-1 agonist) in 155 biopsy-proven NASH/MASH patients. As a result, tirzepatide became the first incretin to hit on fibrosis with a 21-25% placebo adjusted response. While there was some read-through to other NASH/MASH stocks such as Madrigal and 89bio (both down approx. -3%), we believe NASH/MASH is a complex disease and high non...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.